Vinorelbine and Prednisone in older Cancer Patients with Hormone-Refractory Metastatic Prostate Cancer a Phase II Study

Hanks G.E. , Myers C.E. , Scardino P.T. : Cancer of the prostate. In: Cancer principles and practice in oncology, De Vita V.T. , Helman S. , Rosenberg S.A. (Eds), pp 1073–1113, JP Lippincott, Philadelphia, 1993.

Pack R. , Spitz M.R. : Epidemiology of prostate cancer with emphasis on familiar clusters. Cancer, 45: 384–390, 1993.

Havlik R.J. , Yancik R. , Long S. , Ries L. , Edwaeds B. : The National Institute of aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer, 74 (Suppl): 2101–2106, 1994.

Yancik R. : Epidemiology of cancer in the elderly. Current status and projections for the future. RAYS, 22: (Suppl 1): 3–9, 1997.

Parker S.L. , Tong T. , Bolden S. , Wingo P.A. : Cancer statistics. Cancer J Clinical, 47: 5–27, 1997.

Klein L.A. : Prostatic carcinoma. N Engl J Med, 300: 26–33, 1968.

Kantoff P.W. : New agents in the therapy of hormone refractory patients with prostate cancer. Semin Oncol, 22: 32–34, 1995.

Oh W.K. , Kantoff P.W. : Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160: 1220–1229, 1998.

Small E.J. , Vogelzang N.J. : Second line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 15: 382–388, 1997.

Budman D.R. : Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest, 15: 475–490, 1997.

Johnson S.A. , Harper P. , Hortobagy G.N. , Pouillart P. : Vinorelbine: an overview. Cancer Treat Rev, 22: 127–142, 1996.

Sorio R. , Robieux I. , Galligioni E. , Freschi A. , Lazzarini R. , Colussi A.M. , Monfardini S. : Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer, 33: 301–303, 1997.

Field-Jones S. , Koletky A. , Wilding G. : Improvement in clinical benefit with vinorelbine in the treatment of hormone refractory prostate cancer: a phase II trial. Ann Oncol, 10: 1307–1310, 1999.

Smith M.R. , Kaufman D. , Oh W. : Vinorelbine and estramustine in androgen independent metatstatic prostate cancer: a phase II study, Cancer, 89: 1824–1828, 2000.

Carles J. , Domenech M. , Gelabert-Mas M. : Phase II study of estramustine and vinorelbine in hormone refractory prostate carcinoma patients. Acta Oncol, 37: 187–191, 1998.

Kilbourn R. , Soble M. , Sethi G. , Snider J. :Results of a phase II trial of mitoxantrone and navelbine for hormone-refractory prostate cancer. Proc ASCO, 18: 322 (abst 1240), 1999.

Melzack R. : The McGill pain questionnaire: major properties and scoring methods. Pain, 1: 277–299, 1975.

Kaplan E. , Meier P. : Nonparametric estimation for incomplete observations. J Am Stat Assoc, 53: 457–481, 1958.

Trump D.L. , Shipley W.U. , Dillioglugil O. , Scardino P.T. : Neoplasm of the prostate. In: Cancer Medicine, Holland J.F. , Bast R.C. , Morton D.L. (Eds), pp 2125–2164, vol 2, 4th edn, Williams & Wilkins, Baltimore, 1997.

Catalona W.J. : Management of cancer of the prostate. N Engl J Med, 331: 996–1004, 1994.

Pagoda A. , Petrylak D. : Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer, 71: 1098–1109, 1993.

Figg W.D. , Ammerman K. , Patronas N. , Steinberg S.M. , Walls R.G. , Dawson N. , Reed E. , Sartor O. : Lack of a correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone refractory prostate cancer. Cancer Invest, 14: 513–514, 1996.

Sabbatini P. , Larson S.M. , Kremer A. , Zhang Z.F. , Jeung H. , Sun M. , Imbriaco M. , Horak I. , Conolli M. , Ding C. , Ouyoung P. , Kelly W.K. , Scher H.I. : Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol, 17: 948–957, 1999.

Scher H.I. , Kelly W.K. : Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol, 11: 1566–1572, 1999.

Tannock I.F. , Osoba D. , Stockier R. , Ernst D.S. , Neville A.J. , Moore M.J. , Armitage G.R. , Wilson J.J. , Venner P.M. , Loppin C.M. , Murphy K.C. : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with a palliative end point. J Clin Oncol, 14: 1756–1764, 1996.

Kantoff P.W. , Halabi S. , Conaway M. , Picus J. , Kirshner S. , Hars V. , Trump D. , Winer E.P. , Vogelzang N.J. : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol, 17: 2056–2513, 1999.

Bloomfield D.J. , Krahn M.D. , Neogi T. , Panzarella T. , Smith D.J. , Warde P. , Willan A.R. , Ernst S. , Moore M.J. , Neville A. , Tannock I.F. : Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer based on a Canadian randomised trial with a palliative end point. J Clin Oncol, 16: 2272–2279, 1998.

Scher H.I. , Kelly W.M. , Zhang Z.E. , Ouyang P. , Sun M. , Schwartz M. , Ding C. , Wang W. , Horak I.D. , Kremer A.B. : Post-therapy serum prostate specific antigen level and survival in patients with androgen independent prostate cancer. J Natl Cancer Inst, 91: 244–251, 1999.

Myers C. , Cooper M. , Stein C. , LaRocca R. , Walther M.M. , Weiss G. , Choyke P. , Dawson N. , Steinberg S. , Uhrich M.M. : Suramin, a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol, 10: 881–889, 1992.

Thalmann G.N. , Sikes R.A. , Chang S.M. , Johnston D.A. , von Eschenbach A.C. , Chun L.W. : Suramin-induced decrease in prostate-specific antigen expression with no effect on tumour growth in the LNCap model of human prostate cancer. J Natl Cancer Inst, 88: 794–801, 1996.

Horti J. , Dixon S.C. , Logothetis C.S. , Guo Y. , Reed E. , Figg W.D. : Increased transcriptional activity of prostate specific antigen in the presence of TNP-470, an angiogenesis inhibitor. Br J Cancer, 79: 1588–1593, 1999.

Smith D.C. , Dunn R.L. , Stradermen M.S. , Rodnej L.D. , Kenneth J.P. : Change in serum prostate specific antigen as a marker of response to cytotoxic therapy for hormone refractory prostate cancer. J Clin Oncol, 16: 1835–1843, 1998.

Dowling A.J. , Panzarella T. , Ernst D.S. : A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer. Ann Oncol, 12: 773–778, 2001.

Smith D.C. : Chemotherapy for advanced prostate cancer. In: American Society of Clinical Oncology Educational Book, Perry M.C. (Ed), pp 585–594, American Society of Clinical Oncology, Alexandria (VA), 2000.

Kornblith A.B. , Herndon J.E. , Zuckerman E. : The impact of docetaxel, estramustine, and low-dose hydrocortisone on the quality of life of men with hormone-refractory prostate cancer and their partners: a feasibility study. Ann Oncol, 12: 633–641, 2001.

Small E.J. , Reese D.M. , Vogelzang N.J. : Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol, 26: 61–67, 1999.

Berry W. , Rohrbaugh T. and the American oncology Resources Clinical Research Task Force: Phase II trial of single agent, weekly taxotere in symptomatic, hormone–refractory prostate cancer (HRPC). Proc ASCO, 18: 335 (abst 1290), 1999.

Picus J. , Schultz M. :A phase II trial of docetaxel in patients with hormone refractory prostate cencer (HRPC): long-term results. Proc ASCO, 18: 314 (abst 1206), 1999.

Sweeney C.J. , Monaco F.J. , Jung S.H. , Waisielewski M.J. , Picus J. , Ansari R.H. , Dugan W.M. , Einhorn L.H. : A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol, 13: 435–440, 2002.

Seidman A. , Scher H.I. , Petrylak D. , Dershaw D.D. , Curley T. : Estramustine and vinblastine: use of prostate-specific antigen as a clinical trial end point for hormone-refractory prostate cancer. J Urol, 147: 931–934, 1992.

Balducci L. , Extermann M. : A practical approach to the older patients with cancer. Curr Probl Cancer, 25: 1–76, 2001.